Drug trials in pediatric heart failure: Hype or improved clinical science?

Future Cardiology

Volumn 2, Issue 3, 2006, Pages 281-286

  Shaddy, Robert E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Congenital heart disease; Drug trials; Heart failure; Pediatrics

Indexed keywords

AMIODARONE; ANTIHISTAMINIC AGENT; BENZYL ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BUCINDOLOL; CHLORAMPHENICOL; CORTICOSTEROID; DIETHYLENE GLYCOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ETANERCEPT; GLUCURONOSYLTRANSFERASE; MOXONIDINE; NORADRENALIN; PHENOBARBITAL; PLACEBO; SULFONAMIDE;

AGE; ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG EXCRETION; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; EVIDENCE BASED MEDICINE; EXCITATION; GROWTH DISORDER; HEART FAILURE; HEART VENTRICLE FUNCTION; HUMAN; HYPERACTIVITY; HYPOTENSION; KIDNEY FAILURE; NORADRENALIN RELEASE; PEDIATRICS; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SEDATION; SURVIVAL RATE;

EID: 33646582314     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.3.281     Document Type: Article

References (27)

1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. 316, 1429-1435 (1987).
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325, 293-302 (1991).
3. Cohn JN, Johnson G, Ziesche S et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325, 303-310 (1991).
4. Bristow MR, Gilbert EM, Abraham WT et al.: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94, 2807-2816 (1996).
5. Packer M, Bristow MR, Cohn JN et al.: The effect of carvedilol on morbidity and mortality In patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349-1355 (1996).
6. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial In Congestive Heart Failure MERIT-HF). Lancet 353, 2001-2007 (1999).
7. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13 (1999).
8. Packer M, Fowler MB, Roecker EB et al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106, 2194-2199 (2002).
9. A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344, 1659-1667 (2001).
10. Anker SD, Coats AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. 86, 123-130 (2002).
11. Kalra PR, Moon JC, Coats AJ: Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol. 85, 195-197 (2002).
12. Cohn JN, Pfeffer MA, Rouleau J et al.: Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur. J. Heart Fail. 5, 659-667 (2003).
13. Derrick GP, Narang I, White PA et al.: Failure of stroke volume augmentation during exercise and dobutamine stress is unrelated to load-independent indexes of right ventricular performance after the Mustard operation. Circulation 102, II154-II159 (2000).
14. Derrick GP, Josen M, Vogel M, Henein MY, Shinebourne EA, Redington AN: Abnormalities of right ventricular long axis function after atrial repair of transposition of the great arteries. Heart 86, 203-206 (2001).
15. Vogel M, Derrick G, White PA et al.: Systemic ventricular function in patients with transposition of the great arteries after atrial repair: a tissue Doppler and conductance catheter study. J. Am. Coll. Cardiol. 43, 100-106 (2004).
16. Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L: Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 96, 1507-1512 (1997).
17. Hechter SJ, Fredriksen PM, Liu P et al.: Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am. J Cardiol. 87, 660-663, A611 (2001).
18. Dore A, Houde C, Chan KL et al.: Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation 112, 2411-2416 (2005).
19. Derrick G, Deanfield JE: Decline in ventricular function and clinical condition after Mustard repair. Eur. Heart J. 25, 1863-1864 (2004).
20. FDA. Guidance for Industry: E11 Clinical Investigation of Medicinal Products in the Pediatric Population (2000).
21. Hoffman TM, Wernovsky G, Atz AM et al.: Prophylactic intravenous use of milrinone after cardiac operation In pediatrics (PRIMACORP) study. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics. Am. Heart. J. 143, 15-21 (2002).
22. Sinaiko AR, Lauer RM, Sanders SP: End points for cardiovascular drug trials in pediatric patients. Am. Heart. J. 142, 229-232 (2001).
23. Flynn JT: Ethics of placebo use in pediatric clinical trials: the case of antihypertensive drug studies. Hypertension 42, 865-869 (20O3).
24. Ross LF, Newburger JW, Sanders SP: Ethical issues in pediatric trials. Am. Heart. J. 142, 233-236 (2001).
25. Institute of Medicine: Small Clinical Trials: Issues and Challenges. Evans C, Ildstad S (Eds), National Academy Press, Washington, DC, USA (2001).
26. Berlin CM Jr: Challenges in conducting pediatric drug trials. J. Allergy Clin. Immunol. 106, S125-S127 (2000).
27. Salazar JC: Pediatric clinical trial experience: government, child, parent and physician's perspective. Pediatr. Infect. Dis. J. 22, 1124-1127 (2003).